BioPharma Nexus Conference’s Post

What's the state of the commercial R&D #antibodydrugconjugates space? The Antibody Society has just released its summary of the commercial antibody therapeutics pipeline that they carefully manually curate. Having reviewed it I've summarised over 400 ADCs and RITs that have been or are in commercial R&D up to Oct 2023. Key insight: It's a competitive space, around relatively few targets with a substantial risk of termination. It's exciting and competitive times for those of us driving #antibodydrugconjugates #scienceandtechnology #innovation #precisionmedicine #pharmacology to help transform patients' lives. The first three rows in the table correspond to the graphs in descending order.

Today we announced groundbreaking enzymatic synthesis data at the #TIDESUSA annual meeting! Codexis has successfully synthesized a full-length, known siRNA oligonucleotide from starting material through the attachment of a conjugation moiety via an enzymatic route to support RNA-based therapeutics manufacturing. RNAi therapeutics key opinion leader John Maraganore noted, “The data presented today by Codexis are truly unprecedented—I believe this is the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety. This milestone provides meaningful proof of process to industry that there are alternative manufacturing methods available as the demand for RNAi therapeutics increases. The ECO Synthesis™ manufacturing platform has the potential to be a scalable and sustainable way to manufacture this important and growing new class of medicines.” Read our press release for more information: https://lnkd.in/d9WquAUY #enzymeengineering #proteinengineering #RNAi #RNAimanufacturing #enzymaticsynthesis

Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar: The global GEP-NET therapeutics market is further expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research...

As per DelveInsight’s analysis, the estimated total diagnosed prevalent Amyotrophic Lateral Sclerosis (ALS) cases in the 7MM were approximately 500K in 2022.  The ALS market size in the 7MM was approximately USD 500 million in 2022, which is expected to grow by 2032. Some of the leading pharma and biotech giants in the Amyotrophic Lateral Sclerosis market include Helixmith, Sanofi, Denali Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Inc., Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine, MediciNova, Inc., Seelos Therapeutics, Inc., Prilenia, AB Science, Eledon Pharmaceuticals, Inc., Revalesio Corporation, Biohaven, UCB, Ra Pharmaceuticals, AI Therapeutics, and others. Learn More: https://lnkd.in/dCfic7-p #healthcarejob #biotechnology #lifesciences #pharmaceutical #market #marketforecast #marketanalysis #clinicaltrials #clinicalresearch #fda #healthcaremarket #healthcareindustry #marketoutlook #amyotrophiclateralsclerosis

New Whitepaper - The pharmaceutical industry’s development of innovative therapies over recent years has been astounding. By modifying genetic material in patients with certain hereditary disorders, these have offered the potential to treat conditions such as cancer, heart disease, diabetes and haemophilia. This free whitepaper from Cygnus Technologies, LLC explores the emergence of host-cell protein (HCP) analytics as a critical weapon in biomanufacturers’ arsenals, helping to ensure trailblazing drugs are as safe and effective as possible. Fill in your details to find out more. Click here to download - https://lnkd.in/dTzUENRr #pharma #hostcell #proteinanalytics #clinicaltrials #drugdevelopment

Thoughts on this? >> Innate ends Ph1b in peripheral T cell lymphoma; Layoffs at NextCure >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #biotech #productmarketing

𝐍𝐞𝐰𝐬 𝐚𝐛𝐨𝐮𝐭 𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 Personalize medicine based on peptide has made great progress in recent years. As more and more clinical projects were initiated the demand for small scale GMP grade peptides was also picking up quickly. Hence, Intavis Peptide Services decided in 2019 to build 𝐚 𝐆𝐌𝐏 𝐀𝐏𝐈 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲. Lo and behold, we are on schedule and eagerly await the opening ceremonies planned for Q4 of 2024. If you are you planning any 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐨𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, don’t hesitate to check out 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞. #gmp #drugdevelopment #peptides #clinicaltrials #intavis

💊 𝐒𝐦𝐚𝐥𝐥 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬 𝐝𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐚𝐦𝐨𝐧𝐠 𝐅𝐃𝐀 𝐧𝐨𝐯𝐞𝐥 𝐝𝐫𝐮𝐠 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐢𝐧 2023 Among the FDA & CDER 2023 novel drug approvals, oncology and haematology are the dominant therapeutic areas. 2023 brought more diversity in terms of modalities, especially bringing an increase in nucleotide-based therapeutics. According to 𝘕𝘢𝘵𝘶𝘳𝘦 𝘙𝘦𝘷𝘪𝘦𝘸𝘴 𝘋𝘳𝘶𝘨 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺, the FDA approved in 2023: ⚆ 34 small molecule products ⚆ 17 protein-based products ⚆ 4 oligonucleotides 𝘞𝘩𝘢𝘵 𝘵𝘳𝘦𝘯𝘥𝘴 𝘪𝘯 𝘵𝘦𝘳𝘮𝘴 𝘰𝘧 𝘮𝘰𝘥𝘢𝘭𝘪𝘵𝘪𝘦𝘴 𝘤𝘢𝘯 𝘸𝘦 𝘦𝘹𝘱𝘦𝘤𝘵 𝘪𝘯 2024? Source: https://lnkd.in/eT_j65eT #pharma #drugdevelopment #biotech #innovation #business #clinicaltrials #womeninbusiness #drjojo

IRLAB Therapeutics AB In our recent analysis conducted with EQL desktop, we have reviewed IRLAB Therapeutics AB, a biopharmaceutical company based in Gothenburg, Sweden. Current Developments: IRLAB's development pipeline includes Mesdopetam in phase IIb/III trials for dyskinesia in Parkinson’s disease and several preclinical initiatives aimed at neurodegenerative disorders. Strategic Approach: Our research provides an objective look into IRLAB’s strategic methods and the progress of their clinical trials, presenting a clear picture of their operations and potential implications for patient care. Sign up today: https://lnkd.in/dJ8zhDrP #ResearchwithAI #EQL #Irlab #marketintelligence